Successful treatment of acute Budd-Chiari syndrome with percutaneous transluminal angioplasty
β Scribed by Y. Shirai; H. Yoshiji; M. Fujimoto; H. Kojima; K. Yanase; T. Namisaki; M. Kitade; K. Yamamoto; H. Sakaguchi; K. Kichikawa; H. Fukui
- Publisher
- Springer
- Year
- 2004
- Tongue
- English
- Weight
- 219 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0942-8925
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Restenosis following coronary angioplasty can usually be treated effectively and safely by repeated angioplasty. However, the presence of a complex lesion morphology may bias the clinician away from angioplasty toward either recommending bypass surgery or continuing medical therapy alone in spite of
## Abstract Gemtuzumab ozogamicin (GO; CMAβ676; Mylotargβ’) is a chemotherapeutic agent approved for the treatment of CD33βpositive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic venoβocclusive disease has been reported to develop as a late complication